Close Menu

NEW YORK – Genetron Health said on Thursday that its fourth quarter revenues were up 30 percent year over year, as sales of sequencing instruments, kits, and LDT testing, all grew significantly.

For the three months ended Dec. 31, 2020, the Chinese precision oncology platform company reported RMB133.9 million (US$20.5 million) for the quarter, up from RMB102.9 million in the same period of 2019.  

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.